Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs Clopidogrel in Stable Coronary Syndrome
NCT05858918Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Oct 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ticagrelor in stable coronary syndrome (SCS), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Dyspnea at 6 months and Major Adverse Cardiovascular Events at 6 months. Started Oct 2022; status: completed.
02
Drugs
ticagrelor
03
Conditions
stable coronary syndrome (SCS)
Beyond the preview
Go deeper on NCT05858918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05858918.